GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Capex-to-Operating-Cash-Flow

Clal Biotechnology Industries (XTAE:CBI) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Clal Biotechnology Industries's Capital Expenditure for the three months ended in Dec. 2023 was ₪0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was ₪0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Clal Biotechnology Industries Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Capex-to-Operating-Cash-Flow Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 - - - -

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow falls into.



Clal Biotechnology Industries Capex-to-Operating-Cash-Flow Calculation

Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.005) / -8.513
=N/A

Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clal Biotechnology Industries  (XTAE:CBI) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Clal Biotechnology Industries Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016

CB&I To Report First Quarter 2018 Financial Results on April 23

By PRNewswire PRNewswire 04-09-2018

CB&I Announces Storage Award for Export Facility in Canada

By PRNewswire PRNewswire 04-26-2018

Dollar Cost Average on CBI

By Jonathan Poland Jonathan Poland 08-17-2017

Van Den Berg Reduces Position in 5-Star Company

By Kyle Ferguson Kyle Ferguson 01-25-2016

McDermott Announces Ethylene Furnace Award in Indonesia

By PRNewswire PRNewswire 01-24-2019

This Warren Buffett Bargain Stock Is Good For A Double

By Jonathan Poland Jonathan Poland 05-27-2015

CB&I Announces Preliminary First Quarter 2018 Financial Results

By PRNewswire PRNewswire 04-12-2018